James Flanagan

Imperial College London

Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics. He was awarded a Breast Cancer Campaign Scientific Fellowship (Imperial, 2009-2014) and is now a Senior Lecturer (2014-present) in the Division of Cancer, Dept. of Surgery and Cancer, Faculty of Medicine at Imperial College London. He was awarded the British Association of Cancer Research Translational Researcher Award in 2011 and is the principal investigator for the OCA funded programme "Risk and Prevention" based in the Ovarian Cancer Action Research Centre. Current research is aimed at investigating epigenetic alterations as a mechanism for carcinogenesis and investigating the hypothesis that epigenetic variation may be a driver of cancer risk whether by inherent constitutional variation or as a mediator of other cancer risk factors.

dont miss

Epigenetic biomarkers for platinum response in ovarian cancer

Platinum based chemotherapy is the standard of care for ovarian cancer patients at first line treatment and often at subsequent relapses. We have identified and validated an epigenetic biomarker detectable in blood DNA that predicts whether a patient should be treated with platinum after relapse. We propose a mechanism by which platinum-adduct DNA repair causes the epigenetic changes and that the genomic and epigenomic location of platinum adducts defines sensitivity.

EVEN MORE SEMINARS

  • Dr Catherine Coyle: Speaking at the Oncology Convention

    Dr Catherine Coyle
    Christie Hospital NHS Foundation Trust

    Prostate Cancer- the non surgical oncologists view

  • Dr Abeer Shabaan: Speaking at the Oncology Convention

    Dr Abeer Shabaan
    Queen Elizabeth Hospital Birmingham & University of Birmingham

    Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations

  • Malcolm Wilson: Speaking at the Oncology Convention

    Malcolm Wilson
    The Colorectal & Peritoneal Oncology Centre, The Christie Hospital NHS Foundation Trust, Manchester

    Cytoreduction and HIPEC in the treatment of peritoneal disease from appendiceal and colorectal tumours

  • Dr Khurum Khan: Speaking at the Oncology Convention

    Dr Khurum Khan
    University College London Hospitals

    Translational research in GI Oncology- how to make progress?

  • Dr Qamar Ghafoor: Speaking at the Oncology Convention

    Dr Qamar Ghafoor
    University Hospital Birmingham

    Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.